MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.24 (+2.07%)

Stability Price

Overvalued by 97.44%

Company Metrics

  • 13.83 P/E
  • 13.67 P/S
  • 2.99 P/B
  • -2.193 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0 / 0% Dividend
  • 468,732.00 Avg. Vol.
  • 611.3M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


momenta pharmaceuticals inc
Businessweek - Jun 26, 2012
Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs.
Momenta Pharmaceuticals, Inc. Pushes Forward
Motley Fool - Nov 5, 2014
At this point, earnings calls for Momenta Pharmaceuticals (NASDAQ: MNTA ) are more an opportunity to update investors than to report revenue and earnings.
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results - MarketWatch
Momenta Pharmaceuticals Inc.: Momenta Pharmaceuticals Reports Third ... - The Wall Street Transcript
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank ...
Nasdaq - Nov 24, 2014
CAMBRIDGE, Mass., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the 2014 ...
Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc. (Fed. Cir ...
Patent Docs - Aug 10, 2012
Momento Pharmaceuticals The case involved a District Court grant of a preliminary injunction to Momenta in litigation between two ANDA filers.
Momenta Pharmaceuticals Inc. Stock Downgraded (MNTA) - Mar 4, 2014
This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the ...
Momenta Pharmaceuticals Heading For A Repeat
Seeking Alpha (registration) - Aug 5, 2014
More importantly going forward, Momenta's 50% share of profits could fill the company's coffers with enough coin to allow further development of proprietary candidates like necuparanib.
Momenta Pharmaceuticals President Sells $25614 in Stock (MNTA)
sleekmoney - 7 hours ago
The stock had a trading volume of 96,260 shares. Momenta Pharmaceuticals has a one year low of $9.38 and a one year high of $19.90.
Insider Selling: Momenta Pharmaceuticals President Unloads 2210 Shares of ... - Intercooler
Company News on Price Target: Momenta Pharmaceuticals , Mindray Medical ... - Fico News Media
Momenta Pharmaceuticals Inc. v. Amphastar Pharmaceuticals, Inc.: "The Rest of ...
Patent Docs - Aug 14, 2012
Chief Judge Rader Judge Rader wrote a vigorous dissent to the panel majority's opinion in Momenta v. Amphastar, disagreeing with the panel majority's interpretation that the "safe harbor" embodied in 35 U.S.
Limitation On Future Patent Protection For Biosimilars? - Mondaq News Alerts (registration)
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor ...
MarketWatch - Nov 6, 2014
About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA.
Momenta Pharmaceuticals (MNTA) Posts Quarterly Earnings Results, Misses ... - WKRB News
3 Things to Watch at Momenta Pharmaceuticals
Motley Fool - Feb 5, 2013
Despite its name, Momenta Pharmaceuticals (NASDAQ: MNTA ) has been losing steam since the end of 2011 with revenue falling 97% in the last nine months.